The FDA this week approved Tandem Diabetes Care‘s (NSDQ:TNDM) t:slim X2 insulin pump with a predictive low glucose suspend feature designed to cut the frequency and duration of hypoglycemia.
The San Diego, Calif.-based company said that upon launch, its new product will also feature Dexcom‘s (NSDQ:DXCM) G6 continuous glucose monitoring system. Tandem expects that the latest iteration of its insulin pump will be available in August.
Get the full story at our sister site, Drug Delivery Business News.
The post Tandem wins FDA nod for insulin pump with predictive low glucose suspend feature appeared first on MassDevice.